Patents by Inventor Alfred E. Slanetz
Alfred E. Slanetz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240000935Abstract: In various embodiments, the present disclosure provides T cell compositions comprising T cells that encode and/or express a T cell receptor (TCR) that binds to a neoantigen associated with a subject's cancer, and are useful for adoptive immunotherapy. Also disclosed are methods for making and/or using T cell compositions described herein.Type: ApplicationFiled: November 24, 2021Publication date: January 4, 2024Applicant: GENEIUS BIOTECHNOLOGY, INC.Inventors: Alfred E. SLANETZ, Walter BARRY
-
Patent number: 11723921Abstract: The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting.Type: GrantFiled: April 13, 2017Date of Patent: August 15, 2023Assignee: GENEIUS BIOTECHNOLOGY, INC.Inventor: Alfred E. Slanetz
-
Publication number: 20230145991Abstract: The invention relates to compositions comprising a heterogeneous population of T cells with reactivity to selected antigens that are useful for adoptive immunotherapy and methods for making the T cell compositions.Type: ApplicationFiled: June 16, 2022Publication date: May 11, 2023Applicant: GENEIUS BIOTECHNOLOGY, INC.Inventors: Alfred E. SLANETZ, Terry Y. NAKAGAWA, Marissa A. HERRMAN
-
Publication number: 20200237819Abstract: The invention relates to compositions comprising a heterogeneous population of T cells with reactivity to selected antigens that are useful for adoptive immunotherapy and methods for making the T cell compositions.Type: ApplicationFiled: June 28, 2017Publication date: July 30, 2020Applicant: Geneius Biotechnology, Inc.Inventors: Alfred E. SLANETZ, Terry Y. NAKAGAWA, Marissa A. HERRMAN
-
Publication number: 20170216357Abstract: The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting.Type: ApplicationFiled: April 13, 2017Publication date: August 3, 2017Inventor: Alfred E. Slanetz
-
Publication number: 20170101625Abstract: The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting.Type: ApplicationFiled: October 28, 2016Publication date: April 13, 2017Inventor: ALFRED E. SLANETZ
-
Publication number: 20170042999Abstract: The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting.Type: ApplicationFiled: October 28, 2016Publication date: February 16, 2017Inventor: ALFRED E. SLANETZ
-
Publication number: 20170043001Abstract: The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting.Type: ApplicationFiled: October 28, 2016Publication date: February 16, 2017Inventor: Alfred E. Slanetz
-
Publication number: 20170042998Abstract: The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting.Type: ApplicationFiled: October 28, 2016Publication date: February 16, 2017Inventor: ALFRED E. SLANETZ
-
Publication number: 20170043000Abstract: The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting.Type: ApplicationFiled: October 28, 2016Publication date: February 16, 2017Inventor: Alfred E. SLANETZ
-
Publication number: 20140099341Abstract: The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting.Type: ApplicationFiled: May 25, 2012Publication date: April 10, 2014Inventor: Alfred E. Slanetz
-
Publication number: 20140012594Abstract: Medical intervention cost reimbursement on a clinical outcome-dependent basis may be implemented through a periodic cost reimbursement instrument, such as an annuity, associated with the delivery of acute or other discrete event medical intervention, such as gene therapy, cell therapy, or medical nanotechnology.Type: ApplicationFiled: December 23, 2011Publication date: January 9, 2014Applicant: GENEIUS BIOTECHNOLOGY INVESTMENTS, LLCInventor: Alfred E. Slanetz
-
Publication number: 20090221436Abstract: The present invention relates to methods for using chemical ligands to determine target function and identify drug leads.Type: ApplicationFiled: January 30, 2009Publication date: September 3, 2009Inventor: Alfred E. SLANETZ
-
Patent number: 6080840Abstract: An intact, assembled T cell receptor (TcR) in soluble form is provided. The soluble TcR is prepared by splicing the extracellular domains of a T cell receptor to the glycosyl phosphatidylinositol (GPI) membrane anchor sequences of Thy-1. The molecule is expressed in the absence of CD3 on the cell surface, and can be cleaved from the membrane by treatment with phosphatidylinositol specific phospholipase C (PI-PLC). The .alpha. and .beta. chains of the soluble molecule are paired in the native conformation as judged by reactivity with the anti-V.sub..beta. 8 monoclonal antibody F23.1, and with the anti-clonotypic monoclonal antibody 1B2. The soluble TcR is a disulfide linked dimer with a molecular mass of 95 kDa on SDS-PAGE under nonreducing conditions, and 47 kDa after reduction.Type: GrantFiled: February 17, 1995Date of Patent: June 27, 2000Inventors: Alfred E. Slanetz, Alfred L. M. Bothwell